Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
本文提供了包含 N-
乙酰精氨酸的 PCSK9 结合
多肽制剂,例如包含 evolocumab 的制剂,与缺乏 N-
乙酰精氨酸的制剂相比,这些制剂的粘度更低。本文还提供了配制此类组合物的方法,其优点在于可以保留某些成分。这种包含 PCSK9 结合
多肽的制剂可用于患者治疗和/或预防 PCSK9 相关疾病、病症和失调。